You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma

Citation Tools

Article menu

Download PDFPDF

Poster Presentation
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Hurwitz H, Crocenzi T, Lohr J, et al
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma
Journal for ImmunoTherapy of Cancer 2014;2:P86. doi: 10.1186/2051-1426-2-S3-P86